The influence of anti-PAD4 on clinical outcome in patients with rheumatoid arthritis participating in the ORAR registry study (n = 395).
| Univariate | Multivariate | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| anti-PAD | anti-PAD | ACPA | Sex | Age at Onset | Disease Duration | Adj. R2* | |||||||
| Std. β | p | Std. β | p | Std. β | p | Std. β | p | Std. β | p | Std. β | p | ||
| mHAQ | 0.039 | 0.440 | −0.012 | 0.806 | 0.028 | 0.569 | 0.090 | 0.064 | −0.260 | < 0.0001 | −0.356 | < 0.0001 | 0.097 |
| DAS28 | 0.103 | 0.043 | 0.033 | 0.479 | 0.219 | < 0.0001 | 0.124 | < 0.0001 | −0.315 | < 0.0001 | −0.348 | < 0.0001 | 0.180 |
| SJC28 | 0.142 | 0.005 | 0.068 | 0.156 | 0.279 | < 0.0001 | 0.076 | 0.110 | −0.135 | 0.014 | −0.258 | < 0.0001 | 0.149 |
| TJC28 | −0.016 | 0.747 | −0.055 | 0.279 | 0.088 | 0.079 | 0.062 | 0.215 | −0.202 | 0.0005 | −0.0233 | < 0.0001 | 0.048 |
| CRP, mg/dl | 0.135 | 0.008 | 0.075 | 0.123 | 0.232 | < 0.0001 | 0.036 | 0.459 | −0.275 | < 0.0001 | −0.255 | < 0.0001 | 0.141 |
| ESR, mm/h | 0.042 | 0.412 | 0.023 | 0.634 | 0.243 | < 0.0001 | −0.063 | 0.199 | −0.206 | 0.0003 | 0.256 | < 0.0001 | 0.116 |
↵* Adjusted R2 represents the multivariate linear regression. Anti-PAD4: antipeptidyl arginine deiminase type 4 antibodies; ACPA: anticitrullinated protein antibodies; ORAR: Oslo Rheumatoid Arthritis register; mHAQ: modified Health Assessment Questionnaire; DAS28: 28-joint count Disease Activity Score; SJC28: 28-joint swollen joint count; TJC28: 28-joint tender joint count; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate.